# Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy

> **NCT06989541** · — · RECRUITING · sponsor: **University of Alberta** · enrollment: 30 (estimated)

## Conditions studied

- Hypogammaglobulinemia, Acquired

## Interventions

- **BIOLOGICAL:** Immune Globulin Intravenous (Human), 10%
- **BIOLOGICAL:** Immune Globulin Subcutaneous (Human), 20% Solution

## Key facts

- **NCT ID:** NCT06989541
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06989541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06989541, "Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06989541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*